Absci reports business updates and first quarter 2024 financial and operating results

Initiated ind-enabling studies for abs-101 in february continuing to advance abs-201 and abs-301 through preclinical studies vancouver, wash. and new york, may 14, 2024 (globe newswire) -- absci corporation (nasdaq: absi), a data-first generative ai drug creation company, today reported financial and operating results for the quarter ended march 31, 2024.
ABSI Ratings Summary
Quant
ABSI Quant Ranking
Sector
Industry
Quant Rating
Quant Score